COMP <GO>
ELAN vs BMRN // ALTMAN Z-SCORE & DEBT/EQUITY
Elanco Animal Health Incorporated (NYSE) VS. BioMarin Pharmaceutical Inc. (NASDAQ) • 15-METRIC TALLY: ELAN 3
— BMRN 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: BMRN
LAST: $24.10 (+4.51%) • MKT CAP: $11.52B
balance-sheet
1.24
LAST: $57.44 (-1.83%) • MKT CAP: $11.33B
balance-sheet
5.57
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELAN VS. BMRN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELAN | BMRN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.00% | 77.70% | -22.70 | BMRN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.50% | 6.00% | -8.50 | BMRN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 21.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.45% | 6.51% | -4.06 | BMRN | /fcf-yield <GO> |
| Operating Margin | -6.00% | 12.70% | -18.70 | BMRN | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 10.80% | -15.70 | BMRN | /net-margins <GO> |
| Revenue Growth (YoY) | 6.20% | 12.90% | -6.70 | BMRN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.24 | 5.57 | -4.33 | BMRN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | BMRN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.9 | 54.4 | -2.50 | BMRN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.95 | +0.01 | ELAN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 26.8x | -6.80 | ELAN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.52B | $11.33B | $195.3M | ELAN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELAN REV | BMRN REV | ELAN GROSS % | BMRN GROSS % | ELAN FCF | BMRN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.71B | $3.22B | 55.0% | 77.7% | $284.0M | $725.0M |
| FY 2024 | $4.44B | $2.85B | 54.9% | 79.7% | $394.0M | $487.4M |
| FY 2023 | $4.42B | $2.42B | — | — | $72.2M | $50.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELAN // BETA 0.96
BMRN // BETA 0.95